keyword
MENU ▼
Read by QxMD icon Read
search

Esmo guidelines

keyword
https://www.readbyqxmd.com/read/30551863/the-role-of-surgery-in-advanced-disease-for-esophageal-and-junctional-cancer
#1
REVIEW
Stefan Mönig, Sander van Hootegem, Mickael Chevallay, Bas P L Wijnhoven
The incidence of esophageal and junctional cancer has been increasing in western industrialized nations in the past 30 years. At the time of diagnosis, approximately 50% of patients with esophageal and junctional cancers have distant metastases and are considered incurable. In the recent ESMO guidelines and the German S3 guidelines, surgical therapy for metastatic disease is not recommended. In spite of these recommendations, the treatment of limited metastatic (oligo-metastastic) esophagogastric cancer is currently undergoing a shift towards a more aggressive therapy...
October 2018: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/30538372/recent-strategies-and-paradigm-shift-in-management-of-hepatic-metastasis-from-colorectal-cancer
#2
Shekhar Gogna, Priya Goyal
The liver is the most common site for metastasis from colorectal cancers (CRCs). There are so many new armamentarium, which have increased the life expectancy and progression-free survival. There are various available guidelines, such as NCCN, ESMO, and ASCO, which provide an insight into the latest modalities and new protocols. We have tried to elucidate into paradigm shift of the management.
December 2018: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/30511044/comparison-of-guidelines-for-the-management-of-rectal-cancer
#3
E Luzietti, G Pellino, S Nikolaou, S Qiu, S Mills, O Warren, P Tekkis, C Kontovounisios
A comparison between NCCN, ESMO and JSCCR Guidelines is presented, concerning the treatment of rectal cancer, with an analysis and discussion of their discrepancies. Differences indicate areas for research.
December 2018: BJS open
https://www.readbyqxmd.com/read/30498702/standard-approach-to-gastrointestinal-stromal-tumors-differences-between-china-and-europe
#4
REVIEW
Lin Tu, Peter Hohenberger, Heike Allgayer, Hui Cao
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. With the considerable research and application of molecular-targeted therapy for GISTs in the last two decades, GISTs have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those by the European Society of Medical Oncology (ESMO), the clinical situations in China are different from those in European countries. There are distinct differences between the clinical practice, diagnostic methods, surgical approach, and availability of new targeted agents in China and those in Europe...
October 2018: Visceral Medicine
https://www.readbyqxmd.com/read/30475956/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-patients-with-metastatic-gastric-cancer-a-jsmo-esmo-initiative-endorsed-by-csco-ksmo-mos-sso-and-tos
#5
K Muro, E Van Cutsem, Y Narita, G Pentheroudakis, E Baba, J Li, M-H Ryu, W I Wan Zamaniah, W-P Yong, K-H Yeh, K Kato, Z Lu, B C Cho, I M Nor, M Ng, L-T Chen, T E Nakajima, K Shitara, H Kawakami, T Tsushima, T Yoshino, F Lordick, E Martinelli, E C Smyth, D Arnold, H Minami, J Tabernero, J-Y Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer was published in 2016, and covered the management and treatment of local, locoregional, locally advanced and metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and The Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic gastric cancer (mGC) in Asian patients...
November 22, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30475943/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-patients-with-metastatic-oesophageal-cancer-a-jsmo-esmo-initiative-endorsed-by-csco-ksmo-mos-sso-and-tos
#6
K Muro, F Lordick, T Tsushima, G Pentheroudakis, E Baba, Z Lu, B C Cho, I M Nor, M Ng, L-T Chen, K Kato, J Li, M-H Ryu, W I Wan Zamaniah, W-P Yong, K-H Yeh, T E Nakajima, K Shitara, H Kawakami, Y Narita, T Yoshino, E Van Cutsem, E Martinelli, E C Smyth, D Arnold, H Minami, J Tabernero, J-Y Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018...
November 22, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30447922/a-rationale-multidisciplinary-approach-for-treatment-of-esophageal-and-gastroesophageal-junction-cancer-accurate-review-of-management-and-perspectives
#7
REVIEW
Antonio Chiappa, Bruno Andreoni, Renzo Dionigi, Lorenzo Spaggiari, Diego Foschi, Gianluca Polvani, Roberto Orecchia, Nicola Fazio, Gabriella Pravettoni, Maria Laura Cossu, Domenico Galetta, Marco Venturino, Carlo Ferrari, Lorenzo Macone, Cristiano Crosta, Bernardo Bonanni, Roberto Biffi
Cancer of the esophagus and of gastroesophageal junction can be cured, even if with lacking cure rate. Different approaches have been developed, mostly when carcinoma has loco-regional pattern. Multimodality therapy showed a survival rate superior than 10% if compared to a single approach. This is a systematic review, carried to assess the following matters: Which therapeutic opportunities are available? Who could benefit of them? Which adverse reactions could possibly verify? How can physicians definitely choose the proper strategy? Which is the role of surgery? We mean to give either General Practitioner or specialists clear and efficient updates about current treatment of this tumour, starting from physical examination...
December 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/30429069/-18-f-fdg-pet-ct-in-locally-advanced-cervical-cancer-a-review
#8
A P Caresia-Aróztegui, R C Delgado-Bolton, S Alvarez-Ruiz, M Del Puig Cózar-Santiago, J Orcajo-Rincon, M de Arcocha-Torres, M J García-Velloso
Cervical cancer is the second most common gynecological cancer worldwide. In locally advanced cervical cancer, 18 F-FDG PET/CT has become important in the initial staging, particularly in the detection of nodal and distant metastasis, aspects with treatment implications and prognostic value. The aims of this study were to review the role of 18 F-FDG PET/CT in uterine cervical cancer, according to the guidelines of the main scientific institutions (FIGO, NCCN, SEGO, SEOM, ESGO, and ESMO) and its diagnostic accuracy compared to conventional radiological techniques, as well as to review the acquisition protocol and its utility in radiotherapy planning, response assessment and detection of recurrence...
November 11, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/30388700/access-to-innovative-medicines-for-metastatic-melanoma-worldwide-melanoma-world-society-and-european-association-of-dermato-oncology-survey-in-34-countries
#9
L Kandolf Sekulovic, J Guo, S Agarwala, A Hauschild, G McArthur, G Cinat, A Wainstein, C Caglevic, P Lorigan, H Gogas, M Alvarez, R Duncombe, C Lebbe, K Peris, P Rutkowski, A Stratigos, A-M Forsea, L De La Cruz Merino, M Kukushkina, R Dummer, C Hoeller, C Gorry, L Bastholt, D Herceg, B Neyns, R Vieira, P Arenberger, M Bylaite-Bucinskiene, N Babovic, M Banjin, K Putnik, V Todorovic, K Kirov, J Ocvirk, A Zhukavets, A Ymeri, I Stojkovski, C Garbe
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018...
October 30, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/30366202/best-practices-for-the-management-of-thymic-epithelial-tumors-a-position-paper-by-the-italian-collaborative-group-for-thymic-malignancies-tyme
#10
REVIEW
Martina Imbimbo, Margaret Ottaviano, Milena Vitali, Alessandra Fabbri, Giovanni Leuzzi, Michele Fiore, Davide Franceschini, Giulia Pasello, Matteo Perrino, Marco Schiavon, Giancarlo Pruneri, Angelo Paolo Dei Tos, Claudia Sangalli, Marina Chiara Garassino, Rossana Berardi, Alessandra Alessi, Giuseppina Calareso, Iacopo Petrini, Marta Scorsetti, Vieri Scotti, Lorenzo Rosso, Federico Rea, Ugo Pastorino, Paolo Giovanni Casali, Sara Ramella, Umberto Ricardi, Laura Abate-Daga, Valter Torri, Annalisa Trama, Giovannella Palmieri, Mirella Marino, Paolo Andrea Zucali
Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions...
December 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/30339769/triplet-therapies-the-new-standard-of-care-for-multiple-myeloma-how-to-manage-common-toxicities
#11
Agne Paner, Tochukwu M Okwuosa, Kristin J Richardson, Edward N Libby
Multiple three drug combination regimens have been approved for the treatment of multiple myeloma in the last few years. Triplets have become the new standard of care for transplant eligible and ineligible patients with newly diagnosed as well as relapsed multiple myeloma. Novel agents have a unique profile of side effects. The management of toxicities is important to maintain quality of life and maximize treatment duration and benefit. Areas covered: This article reviews efficacy data, incidence of key adverse events and provide recommendations and expert opinion regarding how to manage common toxicities in triplet therapies...
October 19, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/30325679/currently-available-first-line-drug-therapies-for-treating-pancreatic-cancer
#12
Jennifer L Olson, Richard J Bold
Pancreatic adenocarcinoma is the 9th most common cancer in the United States and the 4th most common cause of cancer-related death given its poor prognosis. Areas covered: The authors have performed a literature search for pertinent published clinical trials, ongoing Phase 3 clinical trials, and current treatment guidelines using PubMed, Clinicaltrials.gov, and NCCN, ASCO, ESMO, and JPS websites. The review itself discusses landmark studies and ongoing research into the chemotherapy regimens recommended by each oncologic society...
October 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/30320989/-follow-up-of-breast-cancer-patients-by-general-practioner
#13
I Veys
In Belgium, breast cancer is the most frequent women's cancer accounting for to 35.3 % of the cases. In 2013, 10,778 newly diagnosed breast cancers have been reported in Belgium. Breast cancer has a relatively good prognosis with a 5 year overall survival of 88 %. Survival will be different regarding the subtype and stage at diagnosis. The review of the literature and the guidelines from ESMO and ASCO regarding the follow-up of patients with early breast cancer will be used as references. International guidelines recommend clinical visits (frequencies depending of the subtypes of breast cancer) with an annual mammography associated with an echography...
2018: Revue Médicale de Bruxelles
https://www.readbyqxmd.com/read/30285223/chronic-myeloid-leukaemia-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#14
A Hochhaus, S Saussele, G Rosti, F-X Mahon, J J W M Janssen, H Hjorth-Hansen, J Richter, C Buske
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30285222/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#15
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann, S Peters
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30285221/management-of-anaemia-and-iron-deficiency-in-patients-with-cancer-esmo-clinical-practice-guidelines
#16
M Aapro, Y Beguin, C Bokemeyer, M Dicato, P Gascón, J Glaspy, A Hofmann, H Link, T Littlewood, H Ludwig, A Österborg, P Pronzato, V Santini, D Schrijvers, R Stauder, K Jordan, J Herrstedt
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30285220/esmo-guidelines-committee
#17
(no author information available yet)
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30285219/waldenstr%C3%A3-m-s-macroglobulinaemia-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#18
E Kastritis, V Leblond, M A Dimopoulos, E Kimby, P Staber, M J Kersten, A Tedeschi, C Buske
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30285218/bone-sarcomas-esmo-paedcan-euracan-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#19
P G Casali, S Bielack, N Abecassis, H T Aro, S Bauer, R Biagini, S Bonvalot, I Boukovinas, J V M G Bovee, B Brennan, T Brodowicz, J M Broto, L Brugières, A Buonadonna, E De Álava, A P Dei Tos, X G Del Muro, P Dileo, C Dhooge, M Eriksson, F Fagioli, A Fedenko, V Ferraresi, A Ferrari, S Ferrari, A M Frezza, N Gaspar, S Gasperoni, H Gelderblom, T Gil, G Grignani, A Gronchi, R L Haas, B Hassan, S Hecker-Nolting, P Hohenberger, R Issels, H Joensuu, R L Jones, I Judson, P Jutte, S Kaal, L Kager, B Kasper, K Kopeckova, D A Krákorová, R Ladenstein, A Le Cesne, I Lugowska, O Merimsky, M Montemurro, B Morland, M A Pantaleo, R Piana, P Picci, S Piperno-Neumann, A L Pousa, P Reichardt, M H Robinson, P Rutkowski, A A Safwat, P Schöffski, S Sleijfer, S Stacchiotti, S J Strauss, K Sundby Hall, M Unk, F Van Coevorden, W T A van der Graaf, J Whelan, E Wardelmann, O Zaikova, J Y Blay
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30285217/appendix-2-medullary-thyroid-cancer-eupdate-published-online-19-february-2018-http-www-esmo-org-guidelines-endocrine-and-neuroendocrine-cancers-thyroid-cancer
#20
(no author information available yet)
No abstract text is available yet for this article.
October 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
167016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"